BACKGROUND: Bronchiolitis obliterans syndrome (BOS), chronic lung allograft rejection, remains an impediment for the function of the transplanted organ. In this study, we defined the role of the microRNA (miRNA) miR-144 in fibroproliferation leading to BOS. METHODS: Biopsy specimens were obtained from 20 lung transplant recipients with BOS((+)) and 19 without BOS((-)). Expression of miR-144 and its target, transforming growth factor-β (TGF-β)-induced factor homeobox 1(TGIF1), were analyzed by real-time polymerase chain reaction and Western blot. Overexpression of miR-144 and luciferase reporter genes were performed to elucidate miRNA-target interactions. The function of miR-144 was evaluated by transfecting fibroblasts and determining the response to TGF-β by analyzing Sma- and Mad-related family (Smads), fibroblast growth factor, TGF-β, and vascular endothelial growth factor. Smooth muscle actin-α-positive stress fibers and F-actin filaments in lung fibroblasts were analyzed by immunofluorescence. RESULTS: Analysis of miR-144 in the biopsy specimens demonstrated 4.1 ± 0.8-fold increases in BOS(+) compared with BOS(-) patients, with a significant reduction in TGIF1 (3.6 ± 1.2-fold), a corepressor of Smads. In vitro transfection confirmed that over-expression of miR-144 results in a reduction in TGIF1 and an increase in SMAD2, SMAD4, fibroblast growth factor-6, TGF-β, and vascular endothelial growth factor. Increasing miR-144 by transfecting, increased smooth muscle actin-α and fibronectin, and knockdown of miR-144 diminished fibrogenesis in MRC-5 fibroblasts. CONCLUSIONS: miR-144 is a critical regulator of the TGF-β signaling cascade and is over-expressed in lungs with BOS. Therefore, miR-144 is a potential target toward preventing fibrosis leading to BOS after lung transplant.
BACKGROUND:Bronchiolitis obliterans syndrome (BOS), chronic lung allograft rejection, remains an impediment for the function of the transplanted organ. In this study, we defined the role of the microRNA (miRNA) miR-144 in fibroproliferation leading to BOS. METHODS: Biopsy specimens were obtained from 20 lung transplant recipients with BOS((+)) and 19 without BOS((-)). Expression of miR-144 and its target, transforming growth factor-β (TGF-β)-induced factor homeobox 1(TGIF1), were analyzed by real-time polymerase chain reaction and Western blot. Overexpression of miR-144 and luciferase reporter genes were performed to elucidate miRNA-target interactions. The function of miR-144 was evaluated by transfecting fibroblasts and determining the response to TGF-β by analyzing Sma- and Mad-related family (Smads), fibroblast growth factor, TGF-β, and vascular endothelial growth factor. Smooth muscle actin-α-positive stress fibers and F-actin filaments in lung fibroblasts were analyzed by immunofluorescence. RESULTS: Analysis of miR-144 in the biopsy specimens demonstrated 4.1 ± 0.8-fold increases in BOS(+) compared with BOS(-) patients, with a significant reduction in TGIF1 (3.6 ± 1.2-fold), a corepressor of Smads. In vitro transfection confirmed that over-expression of miR-144 results in a reduction in TGIF1 and an increase in SMAD2, SMAD4, fibroblast growth factor-6, TGF-β, and vascular endothelial growth factor. Increasing miR-144 by transfecting, increased smooth muscle actin-α and fibronectin, and knockdown of miR-144 diminished fibrogenesis in MRC-5 fibroblasts. CONCLUSIONS:miR-144 is a critical regulator of the TGF-β signaling cascade and is over-expressed in lungs with BOS. Therefore, miR-144 is a potential target toward preventing fibrosis leading to BOS after lung transplant.
Authors: S Shenoy; T Mohanakumar; G Todd; W Westhoff; K Dunnigan; D R Adkins; R A Brown; J F DiPersio Journal: Bone Marrow Transplant Date: 1999-02 Impact factor: 5.483
Authors: Angali Golocheikine; Dilip S Nath; Haseeb Ilias Basha; Deepti Saini; Donna Phelan; Aviva Aloush; Elbert P Trulock; Ramsey R Hachem; G Alexander Patterson; Joseph M Ahearn; Thalachallour Mohanakumar Journal: J Heart Lung Transplant Date: 2010-04 Impact factor: 10.247
Authors: A Magnan; J L Mege; J C Escallier; J Brisse; C Capo; M Reynaud; P Thomas; B Meric; L Garbe; M Badier; L Viard; P Bongrand; R Giudicelli; D Metras; P Fuentes; D Vervloet; M Noirclerc Journal: Am J Respir Crit Care Med Date: 1996-04 Impact factor: 21.405
Authors: T S Worst; K Daskalova; A Steidler; K Berner-Leischner; R Röth; B Niesler; C-A Weis; M C Kriegmair; P Erben; D Pfalzgraf Journal: World J Urol Date: 2017-06-20 Impact factor: 4.226
Authors: Lingyin Ge; David M Habiel; Phil M Hansbro; Richard Y Kim; Sina A Gharib; Jeffery D Edelman; Melanie Königshoff; Tanyalak Parimon; Rena Brauer; Ying Huang; Jenieke Allen; Dianhua Jiang; Adrianne A Kurkciyan; Takako Mizuno; Barry R Stripp; Paul W Noble; Cory M Hogaboam; Peter Chen Journal: JCI Insight Date: 2016-12-08
Authors: Z Xu; S Ramachandran; M Gunasekaran; D Nayak; N Benshoff; R Hachem; A Gelman; T Mohanakumar Journal: Am J Transplant Date: 2016-02-04 Impact factor: 8.086